Premenstrual Dysphoric Disorder: Epidemiology and Treatment.
Premenstrual Dysphoric Disorder: Epidemiology and Treatment.
复制标题
DOI：
10.1007/s11920-015-0628-3
复制
发表时间：
2015-11
影响因子：
6.7
通讯作者：
Epperson CN
中科院分区：
文献类型：
--
作者：
Hantsoo L;Epperson CN
经前焦虑症(PMDD)最近被指定为DSM-5中的一种障碍，为进一步研究提供了一系列途径。PMDD的特征是在月经期前出现认知-情感症状，在症状和周期性方面与其他情感障碍的特征不同。神经类固醇可能是PMDD临床表现和病因的关键因素，并代表着一种潜在的药物开发途径。这篇综述将介绍有关PMDD病理生理学的潜在因素的最新文献，包括神经类固醇和应激，并探索潜在的治疗靶点。
Recently designated as a disorder in the DSM-5, premenstrual dysphoric disorder (PMDD) presents an array of avenues for further research. PMDD's profile, characterized by cognitive–affective symptoms during the premenstruum, is unique from that of other affective disorders in its symptoms and cyclicity. Neurosteroids may be a key contributor to PMDD's clinical presentation and etiology, and represent a potential avenue for drug development. This review will present recent literature on potential contributors to PMDD's pathophysiology, including neurosteroids and stress, and explore potential treatment targets.